Ikena Oncology presented results of a clinical trial of IK-007 in patients with advanced microsatellite stable colorectal cancer at ESMO Immuno-Oncology Annual Congress 2022. For details, please refer an abstract of the presentation at congress homepage.
161P: A Phase 1b Study to Evaluate IK-007 in combination with Pembrolizumab (pembro) in Patients with AdvancedMicrosatellite Stable (MSS) Colorectal Cancer (CRC))
https://cslide.ctimeetingtech.com/immuno22hybrid/attendee/confcal/session/calendar?q=161P
